1h Free Analyst Time
The orthostatic hypotension drugs market is forecasted to grow by USD 537.4 million during 2023-2028, accelerating at a CAGR of 7.7% during the forecast period. The report on the orthostatic hypotension drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of oh in geriatric population, increasing prevalence of chronic diseases associated with high risk of oh, and high market growth opportunities for oh drugs in emerging countries.
The orthostatic hypotension drugs market is segmented as below:
By Product
- Midodrine
- Northera (droxidopa)
- Fludrocortisone
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the orthostatic hypotension drugs market covers the following areas:
- Orthostatic Hypotension Drugs Market sizing
- Orthostatic Hypotension Drugs Market forecast
- Orthostatic Hypotension Drugs Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Product
9 Customer Landscape
10 Geographic Landscape
11 Drivers, Challenges, and Opportunity/Restraints
12 Competitive Landscape
13 Competitive Analysis
14 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global orthostatic hypotension drugs market: Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals PLC, Baxter International Inc., Brancaster Pharma Ltd., Enaltec Labs Pvt. Ltd., Endo International PLC, H Lundbeck AS, Hikma Pharmaceuticals PLC, Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is research and development of new drugs for oh treatment."
According to the report, one of the major drivers for this market is the increasing prevalence of oh in geriatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alchemy Laboratories Pvt Ltd.
- Alembic Pharmaceuticals Ltd.
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- Avadel Pharmaceuticals plc
- Baxter International Inc.
- Brancaster Pharma Ltd.
- Enaltec Labs Pvt. Ltd.
- Endo International Plc
- H Lundbeck AS
- Hikma Pharmaceuticals Plc
- Manus Aktteva Biopharma LLP
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Theravance Biopharma Inc.
- Viatris Inc.
